

The Medical Letter[®]

on Drugs and Therapeutics

Volume 65

Published online April 3, 2023

Online
Article

IN THIS ISSUE

Fam-trastuzumab deruxtecan (*Enhertu*) for Breast Cancer

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 65

Published online April 3, 2023

Online
Article

IN THIS ISSUE

Fam-trastuzumab deruxtecan (*Enhertu*) for Breast Cancer

IN BRIEF

Fam-trastuzumab deruxtecan (*Enhertu*) for Breast Cancer

Fam-trastuzumab deruxtecan-nxki (*Enhertu* – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of **HER2-positive** breast cancer based on its rate and duration of response,¹ has been granted regular approval for treatment of adults with unresectable or metastatic HER2-positive breast cancer who received a prior anti-HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and developed recurrence during or within 6 months of completing treatment.

Fam-trastuzumab deruxtecan has also been approved by the FDA for treatment of unresectable or metastatic **HER2-low** breast cancer in patients who received prior chemotherapy for metastatic disease or who developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. It is the first HER2-directed therapy to be approved for patients with HER2-low metastatic breast cancer.

Pronunciation Key

Fam-trastuzumab deruxtecan-nxki: fam tras tooz' ue mab der' ux tee' kan

Enhertu: en her' too

The four-letter suffix -nxki has no pronunciation or meaning; such suffixes are added to biologic drugs to distinguish reference products from their biosimilars.

STANDARD TREATMENT – Both the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) recommend a combination of the anti-HER2 monoclonal antibodies trastuzumab (*Herceptin*) and pertuzumab (*Perjeta*) plus a taxane for first-line treatment of most patients with advanced **HER2-positive** breast cancer.

NCCN and ASCO guidelines were recently updated to include fam-trastuzumab deruxtecan as a preferred second-line option.^{2,3}

About 60% of **HER2-negative** metastatic breast cancers express low levels of HER2. NCCN guidelines recommend fam-trastuzumab as a preferred systemic treatment option for patients with unresectable or metastatic HER2-low (immunohistochemical [IHC] score of 1+ or IHC score of 2+ and a negative result on *in situ* hybridization [ISH-]) breast cancer. HER2-low was previously classified as HER2-negative.⁴

MECHANISM OF ACTION – HER2, a transmembrane receptor protein involved in normal cell growth, is overexpressed in about 20% of breast cancers. Amplification and/or overexpression of HER2 is associated with more aggressive disease and reduced survival. *Enhertu* contains the humanized anti-HER2 monoclonal antibody fam-trastuzumab covalently linked to a topoisomerase I inhibitor payload. Fam-trastuzumab binds to HER2 on tumor cells and delivers DXd, resulting in apoptosis and cell death.

CLINICAL STUDIES – Regular FDA approval of fam-trastuzumab deruxtecan for **HER2-positive** breast cancer was based on the results of an open-label trial (DESTINY-Breast03) in 524 patients with unresectable or metastatic HER2-positive breast cancer that had progressed during or after treatment with trastuzumab and a taxane. Patients were randomized to receive fam-trastuzumab deruxtecan 5.4 mg/kg or trastuzumab emtansine 3.6 mg/kg IV every 3 weeks. Median progression-free survival (PFS) was not reached with fam-trastuzumab deruxtecan and was 6.8 months with trastuzumab emtansine. At 12 months, median PFS was 75.8% with fam-trastuzumab deruxtecan and 34.1% with trastuzumab emtansine.⁵

FDA approval of fam-trastuzumab deruxtecan for **HER2-low** breast cancer was based on the results of an open-label trial (DESTINY-Breast04) in 557 patients with unresectable or metastatic HER2-low breast cancer who received 1-2 prior lines of chemotherapy and were randomized to receive fam-trastuzumab deruxtecan (5.4 mg/kg IV once every 3 weeks) or investigator-selected chemotherapy (capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel). About 89% of patients had hormone receptor-positive disease; median PFS in such patients was 10.1 months with fam-trastuzumab deruxtecan and 5.4 months with investigator-selected chemotherapy and median overall survival was 23.9 months with fam-trastuzumab deruxtecan and 17.5 months with chemotherapy; these differences were statistically significant. Among the overall patient population, median PFS was 9.9 months in the fam-trastuzumab deruxtecan group and 5.1 months in the chemotherapy group and overall survival was 23.4 months with fam-trastuzumab deruxtecan and 16.8 months with chemotherapy; these differences were also statistically significant.⁶

ADVERSE EFFECTS – Fam-trastuzumab deruxtecan can cause nausea, myelosuppression, decreased hemoglobin levels, vomiting, alopecia, increases in liver enzymes, fatigue, and musculoskeletal pain. The label contains a boxed warning about the risks of interstitial lung disease and pneumonitis associated with use of the drug.

DOSAGE, ADMINISTRATION, AND COST – The recommended dosage of fam-trastuzumab deruxtecan is 5.4 mg/kg given intravenously

once every 3 weeks until disease progression or unacceptable toxicity occurs. The labeling specifies a number of dosage adjustments that should be made if adverse effects occur. One dose of *Enhertu* for a 70-kg patient costs about \$9700.⁷

CONCLUSION – Fam-trastuzumab deruxtecan (*Enhertu*) is FDA-approved for treatment of unresectable or metastatic HER2-positive or HER2-low breast cancer. In clinical trials, the drug extended progression-free survival in previously treated patients. Fam-trastuzumab is now a preferred option for second-line treatment of unresectable or metastatic HER2-positive breast cancer and a preferred systemic treatment option for unresectable or metastatic HER2-low breast cancer. ■

1. Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa). *Med Lett Drugs Ther* 2020; 62:182.
2. SH Giordano et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update summary. *J Oncol Pract* 2018; 14:501.
3. NCCN. NCCN guidelines for patients. Metastatic breast cancer, 2022. Available at: <https://bit.ly/415nIOv>. Accessed March 30, 2023.
4. P Tarantino et al. HER2-low breast cancer: pathological and clinical landscape. *J Clin Oncol* 2020; 38:1951.
5. J Cortes et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. *N Engl J Med* 2022; 386:1143.
6. S Modi et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med* 2022; 387:9.
7. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource@ Monthly. March 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2023. ISSN 1523-2859

The
Medical
Letter